Glioblastoma: Pathology and genetics

Christian Hartmann; Pieter Wesseling

doi:10.1016/B978-0-12-801238-3.65070-5

Glioblastoma: Pathology and genetics

Christian Hartmann, Pieter Wesseling

Research related

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Glioblastomas are by far the most frequent and the most malignant tumors originating in the parenchyma of the central nervous system (CNS). In the revised 4th edition of the WHO classification of CNS tumors (published in 2016), classification of these gliomas has fundamentally changed as for the first time presence or absence of particular molecular aberrations is now part of their definition. This review discusses current insights in characteristics of the main molecular subgroups of glioblastoma and how the paradigm shift of a purely histologic towards a histomolecular classification of gliomas has impacted the clinical diagnosis of these tumors.

Original language	English
Title of host publication	Encyclopedia of Cancer
Publisher	Elsevier
Pages	165-178
Number of pages	14
ISBN (Electronic)	9780128124857
DOIs	https://doi.org/10.1016/B978-0-12-801238-3.65070-5
Publication status	Published - 1 Jan 2018

Keywords

EGFR amplification
Glioblastoma
Glioma
H3 k27m mutation
Histopathology
IDH1/IDH2 mutation
Molecular diagnostics
TERT promoter mutation
WHO classification

Access to Document

10.1016/B978-0-12-801238-3.65070-5

Cite this

@inbook{4e322f5eeb8c45a0859f0bfd014eb8da,

title = "Glioblastoma: Pathology and genetics",

abstract = "Glioblastomas are by far the most frequent and the most malignant tumors originating in the parenchyma of the central nervous system (CNS). In the revised 4th edition of the WHO classification of CNS tumors (published in 2016), classification of these gliomas has fundamentally changed as for the first time presence or absence of particular molecular aberrations is now part of their definition. This review discusses current insights in characteristics of the main molecular subgroups of glioblastoma and how the paradigm shift of a purely histologic towards a histomolecular classification of gliomas has impacted the clinical diagnosis of these tumors.",

keywords = "EGFR amplification, Glioblastoma, Glioma, H3 k27m mutation, Histopathology, IDH1/IDH2 mutation, Molecular diagnostics, TERT promoter mutation, WHO classification",

author = "Christian Hartmann and Pieter Wesseling",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-801238-3.65070-5",

language = "English",

pages = "165--178",

booktitle = "Encyclopedia of Cancer",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Glioblastoma

T2 - Pathology and genetics

AU - Hartmann, Christian

AU - Wesseling, Pieter

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Glioblastomas are by far the most frequent and the most malignant tumors originating in the parenchyma of the central nervous system (CNS). In the revised 4th edition of the WHO classification of CNS tumors (published in 2016), classification of these gliomas has fundamentally changed as for the first time presence or absence of particular molecular aberrations is now part of their definition. This review discusses current insights in characteristics of the main molecular subgroups of glioblastoma and how the paradigm shift of a purely histologic towards a histomolecular classification of gliomas has impacted the clinical diagnosis of these tumors.

AB - Glioblastomas are by far the most frequent and the most malignant tumors originating in the parenchyma of the central nervous system (CNS). In the revised 4th edition of the WHO classification of CNS tumors (published in 2016), classification of these gliomas has fundamentally changed as for the first time presence or absence of particular molecular aberrations is now part of their definition. This review discusses current insights in characteristics of the main molecular subgroups of glioblastoma and how the paradigm shift of a purely histologic towards a histomolecular classification of gliomas has impacted the clinical diagnosis of these tumors.

KW - EGFR amplification

KW - Glioblastoma

KW - Glioma

KW - H3 k27m mutation

KW - Histopathology

KW - IDH1/IDH2 mutation

KW - Molecular diagnostics

KW - TERT promoter mutation

KW - WHO classification

UR - http://www.scopus.com/inward/record.url?scp=85079107936&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801238-3.65070-5

DO - 10.1016/B978-0-12-801238-3.65070-5

M3 - Chapter

AN - SCOPUS:85079107936

SP - 165

EP - 178

BT - Encyclopedia of Cancer

PB - Elsevier

ER -

Glioblastoma: Pathology and genetics

Abstract

Keywords

Access to Document

Fingerprint

Cite this